← Eichor
Condition: Her2 Negative Breast Cancer Brain Metastases Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Negative Breast Cancer Brain Metastases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06839560Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06418594Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative B
Phase 2 · 3 location(s) · Roswell Park Cancer Institute · NCT04348747MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
NA · 1 location(s) · Sunnybrook Health Sciences Centre · NCT06247449Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and A
Phase 2 · 1 location(s) · University of Rochester · NCT04965064Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07396454A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871Asciminib in HER2+ Breast Cancer Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Duke University · NCT07136428A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
Phase 2 · 25 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05872347Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Phase 1/Phase 2 · 86 location(s) · Stemline Therapeutics, Inc. · NCT05386108DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Phase 2 · 3 location(s) · Sarah Sammons, MD · NCT06176261UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT05535413A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With
Phase 2 · 17 location(s) · Biostar Pharma, Inc. · NCT06764940
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.